Recent Updates
Recently added Catalysts
BFRI Neutral Sentiment Score: 60/100

Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025

Thursday, November 6, 2025 1 min read
Key Takeaway: Biofrontera Inc. will report its financial results for the third quarter of 2025 on November 12, 2025, following the close of U.S. markets. A conference call is scheduled for November 13, 2025, at 10:00 AM ET to discuss the results and provide a business update. The company specializes in dermatological products and is focused on treatments for skin conditions including non-melanoma skin cancers and acne.

Market Sentiment Analysis

POSITIVE FACTORS

  • Biofrontera is actively updating stakeholders with financial results.
  • The company is focusing on dermatological conditions, which is a growing market.
  • The scheduled conference call provides an opportunity for transparent communication with investors.

Full Press Release Details

WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on Wednesday, November 12, 2025. The company will host a conference call on Thursday, November 13 at 10:00am Eastern Time to discuss those results, provide a business update and answer questions.
Conference Call and Webcast Information
Event: Biofrontera Inc. Third Quarter 2025 Financial Results and Business Update Conference Call
Date: Thursday, November 13, 2025
Time: 10:00am ET
Conference Call: 1-877-877-1275 (U.S.) 1-412-858-5202 (international)
Webcast: Webcast - Biofrontera Inc. 3Q25 Results Conference Call
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.
shamsian@lythampartners.com

Tags

biopharmaceutical company
dermatological products
Report Third Quarter 2025

Frequently Asked Questions

When will Biofrontera release its financial results?

Biofrontera will report its financial results on November 12, 2025.

What date is the conference call scheduled for?

The conference call is set for November 13, 2025, at 10:00 AM ET.

How can I join Biofrontera's conference call?

Dial 1-877-877-1275 for U.S. callers or 1-412-858-5202 internationally.

What does Biofrontera specialize in?

Biofrontera focuses on dermatological products and photodynamic therapy.

Where can I find more information about Biofrontera?

Visit www.biofrontera-us.com or follow them on LinkedIn and X.

Tags: BFRI Viatris Investor Conferences Healthcare Biofrontera financial results dermatological products conference call
Last updated: Nov 6, 2025